Evidence map›Paper›PMID 37203319›Full record

ArticleAnales del sistema sanitario de Navarra2023

[Corticoid treatment and SARS-CoV-2 variants: two independent factors associated with COVID-19 mortality in a Spanish regional hospital].

Juan Salas Jarque, Javier Moreno Díaz, Cristina Bustos Morell, Javier Pereira Boan, Antonio Durán Portella, Francisco Ruiz Montes, José Velilla Marco

Open access · diamondAbstract readEnglish Abstract
In one paragraph

Article in Anales del sistema sanitario de Navarra, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Juan Salas JarqueFacultad de Medicina. Universidad de Zaragoza. Zaragoza. España. jsjarque@gmail.com.
Javier Moreno DíazDirección Médica. Hospital Royo Villanova. Zaragoza. España.. javimorenomdr@hotmail.com.
Cristina Bustos MorellServicio de Farmacia. Hospital de Barbastro. Barbastro. España.. cbustos@salud.aragon.es.
Javier Pereira BoanServicio de Microbiología. Hospital de Barbastro. Barbastro. España.. jpereiraboan@gmail.com.
Antonio Durán PortellaServicio de Admisión y Documentación. Hospital de Barbastro. Barbastro. España.. aduran@salud.aragon.es.
Francisco Ruiz MontesServicio de Admisión y Documentación. Hospital de Barbastro. Barbastro. España.. fruiz@salud.aragon.es.
José Velilla MarcoFacultad de Medicina. Universidad de Zaragoza. Zaragoza. España.. jvelillam@gmail.com.
Centro de Salud Casa del Barco · ESUniversidad de Zaragoza · ESHospital Royo Villanova · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPandemic inter-wave hospital admissions and COVID-19-related mortality rates vary greatly. Some of the factors that may be playing part in this are the profile of the patients, viral variants, pharmacological treatments, or preventive measures. This work aimed to analyze the factors associated with mortality in COVID-19 patients admitted to hospital during 2020-2021.

methodsRetrospective cohort study with COVID-19 patients admitted to Hospital de Barbastro (Spain) during 2020-2021. Data were collected from the Spanish Conjunto Mínimo Básico de Datos and microbiology and electronic prescription records.

resultsDuring the study period, 908 patients were consecutively admitted for COVID-19 (median age 70 years, 57.2% males); 162 (17.8%) patients died. We identified seven successive epidemiological waves. The following variables significantly associated to higher mortality: age, arterial hypertension, chronic renal failure, dementia, chronic obstructive pulmonary disease, heart failure, prior stroke, Charlson index, and wave 2; wave 4 was associated to greater survival. The multivariate analysis showed that age (OR=1.11; 95% CI: 1.09-1.14), chronic obstructive pulmonary disease (OR=2.33; 95% CI: 1.18-4.57), wave 2 (OR=2.57; 95% CI: 1.10-6.00), and wave 3 (OR=2.94; 95% CI: 1.17-7.38) associated with higher mortality. Glucocorticoid treatment was the only protective factor (OR=0.29; 95%CI: 0.14-0.62).

conclusionsThis study confirms the therapeutic utility of glucocorticoids to reduce in-hospital mortality due to COVID-19. Heterogeneous mortality rates between the different COVID-19 waves suggest a direct role of viral variants as determinants of lethality, regardless of the patient's history.

Indexed as

COVID-19Pulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesAgedFemaleHospitalsHumansMaleRetrospective StudiesSARS-CoV-2Adrenal Cortex Hormones

Identifiers

PMID37203319
PMCPMC10205026
OpenAlexW4367050943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.